Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose metronomic oral paclitaxel with ritonavir in advanced cancer
NL-OMON21795Phase 1Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paclitaxel and ritonavir in cancer, sponsored by Netherlands Cancer Institute. Primary endpoint: Safety and feasibility. Started Sep 2011; status: recruiting.
02
Drugs
paclitaxelritonavir
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON21795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21795.